# GLOW blend FAQ — common questions about GHK-Cu + BPC-157 + TB-500 > Answers to common questions about the GLOW research-peptide blend: ingredients, mechanism, telehealth status, FDA Category 2 posture, WADA classification, combination evidence, and per-component risks. What readers most often ask about the GLOW research-peptide blend, with answers grounded in the published literature and the current regulatory posture. ## What is the GLOW peptide blend and what is actually in it? GLOW is a research-peptide co-formulation of three separate peptides reconstituted in a single vial: GHK-Cu (a copper-binding tripeptide), BPC-157 (a fifteen-amino-acid pentadecapeptide derived from a protein in human gastric juice), and TB-500 (a seventeen-amino-acid synthetic fragment of thymosin beta-4) [16]. Typical advertised vial content is 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500, though this ratio is a vendor convention rather than something derived from any published study. The 'GLOW' name itself is community-derived and does not appear in the peer-reviewed literature [16]. ## How do GHK-Cu, BPC-157, and TB-500 work together in the GLOW blend? Each component targets a different repair pathway. GHK-Cu modulates extracellular-matrix gene expression — collagen, elastin, proteoglycans, MMP/TIMP balance — and damps inflammatory cytokine output [2]. BPC-157 drives angiogenesis through the VEGFR2-Akt-eNOS pathway and supports cytoprotection across vascular, tendon, and gut tissue in rodent models [7, 8]. TB-500 sequesters monomeric G-actin, enabling rapid cytoskeletal remodeling and cell migration [11]. The synergy rationale stacks all three because matrix, vasculature, and migration are three sequential needs of wound repair. The synergy is mechanistic hypothesis, not evidence — the combination itself has not been studied [16]. ## Can I get the GLOW blend via telehealth? This question is what 'telehealthglow.com' is named for, and the honest answer is that the regulatory frame around GLOW makes the question more complicated than it might appear. As of September 2023, BPC-157 sits on the FDA's Category 2 bulk drug substances list, which blocks 503A and 503B compounding pharmacies from preparing it for human use. Injectable GHK-Cu and TB-500 face related restrictions. Telehealth prescribing of GLOW or its components for human use is not consistent with this regulatory posture [16]. This site does not provide telehealth services, prescriptions, referrals, or product sales — we are an independent editorial publisher summarizing the research literature. ## Is the GLOW blend prescribed via telehealth in the United States? The telehealth peptide-prescribing landscape grew rapidly from 2020 through 2023 and contracted sharply after the September 2023 FDA Category 2 listing of BPC-157. Compounding restrictions, state medical board attention, and payment-processor risk policies have together narrowed the channels through which GLOW or its components were previously offered for human use [16]. We do not publish a list of providers and do not have a position on individual prescribing practices — those are between a clinician, a patient, and the relevant regulators. We do publish what the FDA's posture is, what WADA's posture is, and what the published literature does and does not say. ## Why is BPC-157 restricted by the FDA — and does that affect the GLOW blend? The FDA's September 2023 decision to add BPC-157 to its Category 2 bulk drug substances list cited concerns about potential immune reactions, manufacturing impurities, and the absence of human safety data [16]. Category 2 status blocks both 503A traditional patient-specific compounding and 503B outsourcing-facility batch compounding from preparing the substance. Because BPC-157 is one of the three components of GLOW, the GLOW blend itself is constrained by the same restriction — a compounding pharmacy cannot legally prepare a co-formulation that includes a Category 2 substance. The TB-500 and injectable GHK-Cu components face related restrictions when intended for injection. ## Has the GLOW blend itself been studied in a clinical trial? No. A search of the indexed literature for any peer-reviewed clinical or preclinical study of the full GHK-Cu + BPC-157 + TB-500 combination returns nothing [16]. Per-component evidence exists — particularly for GHK-Cu in wound healing [1] and for full-length thymosin beta-4 in ophthalmology [12] — but the three-component combination has not been studied. The two-component BPC-157 + TB-500 subset (the 'Wolverine' stack) also lacks a controlled combination trial. Synergy claims for GLOW are mechanistic extrapolation, not data. ## What does the research say about each GLOW component? GHK-Cu has the longest research record. Its 1994 diabetic-ulcer trial reported wound closure roughly three times faster than placebo [1], and Pickart's 2014 transcriptomic work showed it modulates expression of about thirty-one percent of the human genome at 1-10 nM [2]. BPC-157 has a deep rodent dataset for tendon, vascular, and gut healing [6, 7, 8, 10], plus three small human pilots (knee pain n=14, interstitial cystitis n=12, IV safety n=2) summarized in a 2025 narrative review [9]. TB-500 inherits the thymosin beta-4 evidence base, which includes a published Phase III ophthalmic trial in neurotrophic keratopathy [12] and rodent cardiac and stroke work [13, 14]. The /research page works through each component channel in detail. ## Is GLOW banned for athletes under WADA rules? Yes — for two of the three components, and effectively for the blend as a whole. The World Anti-Doping Agency classifies BPC-157 under category S0 (Non-Approved Substances), prohibited at all times, with no therapeutic-use exemption pathway [16]. Thymosin beta-4 (and by extension TB-500) is classified under S2 (Peptide Hormones, Growth Factors and Related Substances), also prohibited at all times. GHK-Cu is not specifically named in the WADA prohibited list, but copper-binding peptides intended to alter tissue remodeling fall under the agency's general framework for unapproved performance-influencing substances. Tested athletes should treat the entire blend as banned. ## What are the typical research doses used in published studies of each component? The most-cited rodent BPC-157 dose is 10 µg/kg intraperitoneal [7, 8, 10]. GHK-Cu has been studied at 1-10 nM in vitro [2], at 0.05-0.2% in topical formulations [1], and at approximately 3 mg/kg intraperitoneal in rodent fibrosis models [4]. TB-500 inherits dose conventions from full-length thymosin beta-4, including 6 mg/kg intraperitoneal in the 2010 rat stroke model [14] and 0.1% topical in the corneal Phase III [12]. The GLOW combination itself has no validated dose — commercial vials advertise 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500 by vendor convention, not by literature-derived guidance [16]. The /dosage page covers research-context dosing in detail. ## What are the known risks or controversies around the components of GLOW? Three broad categories. First, none of the three components is FDA-approved for any human therapeutic indication, and BPC-157 was placed on the FDA Category 2 bulk drug substances list in September 2023, citing immune-reaction, manufacturing-impurity, and human-safety-data concerns [16]. Second, BPC-157's potent angiogenic effect has prompted theoretical concern about tumor neovascularization — no human data shows a causal link, but the mechanism makes the concern plausible [9, 18]. Third, vendor-supplied GLOW vials vary widely in component ratios, sterility testing, and third-party purity verification, and most published efficacy data is rodent intraperitoneal, which is a substantial inferential leap from human subcutaneous self-administration [16]. ## Is this site selling the GLOW blend or referring me to a provider? No. Telehealth GLOW is an independent editorial publisher. We summarize peer-reviewed research on GHK-Cu, BPC-157, TB-500, and the GLOW blend. We are not a clinic, we do not employ clinicians, we do not provide medical advice, and we do not manufacture, sell, distribute, or refer for any product. The 'telehealth' in our name is editorial framing — a position the publisher occupies relative to a fast-moving prescribing landscape, not a service we offer. See /about for the full editorial-entity statement. ## Why does the design split every heading into three offset color channels? The chromatic-aberration / RGB-split visual treatment is a deliberate editorial argument. GLOW is three separately-studied components presented as one blend, and the three colors literalize that decomposition — red for GHK-Cu (matrix), green for BPC-157 (angiogenesis), blue for TB-500 (migration). The three only fully superimpose in a few places on the site, just as the three peptides almost-but-do-not-quite combine into a single research record. Body text and small UI text stay clean off-white on near-black for AAA legibility — the chromatic split is strictly a display-heading treatment, gated behind prefers-reduced-motion for users who request it. --- An independent editorial reading of three separately-studied research peptides — not a clinic, not a vendor, not a prescription.